# Remote Measurement-Based Care Interventions for Mental Health: Systematic Review and Meta-Analysis

**Authors:** Felix Machleid, Twyla Michnevich, Leu Huang, Louisa Schröder-Frerkes, Caspar Wiegmann, Toni Muffel, Jakob Kaminski

PMC · DOI: 10.2196/63088 · JMIR Mental Health · 2026-01-28

## TL;DR

This study reviews how remote monitoring tools like RMBC can help manage mental health by tracking symptoms and improving treatment outcomes.

## Contribution

The paper provides a systematic review and meta-analysis of RMBC interventions for mental health, highlighting their potential and limitations.

## Key findings

- RMBC interventions showed small but significant effects on symptom-specific outcomes like mania and empowerment.
- Adherence to RMBC tracking was 74.5% on average, with more frequent prompts reducing adherence.
- Few RCTs were available, and most had moderate risk of bias, suggesting limited strong evidence for clinical effectiveness.

## Abstract

Poor management of mental health conditions leads to reduced adherence to treatment, prolonged illness, unnecessary rehospitalization, and a significant financial burden to the health care system. Recognizing this, ecological momentary assessment (EMA) and remote measurement-based care (RMBC) interventions have emerged as promising strategies to address gaps in current care systems. They provide a convenient means to continuously monitor patient-reported outcomes, thereby informing clinical decision-making and potentially improving outcomes such as psychopathology, relapse, and quality of life.

This systematic review and meta-analysis aims to comprehensively appraise and analyze the existing evidence on the use of EMA and RMBC for people living with mental illness.

The study was conducted according to PRISMA-P (Preferred Reporting Items for Systematic Review and Explanation Meta-Analysis Protocols) guidelines and preregistered with the PROSPERO systematic review registry. A comprehensive search was conducted in 4 online databases using Medical Subject Headings terms related to mental disorders and digital technologies. Studies were included if they included adults with a formally diagnosed mental disorder and measured symptoms using EMA or RMBC. Studies were independently reviewed by subgroups of authors, and data were extracted focusing on symptom-focused or disease-specific outcomes, relapse, recovery-focused outcomes, global functioning, quality of life, and acceptability of the intervention. We performed a descriptive analysis of demographic variables and a meta-analysis of randomized controlled trials (RCTs). Risk of bias was assessed using the Cochrane risk-of-bias tool for randomized trials version 2 (RoB-2).

The systematic review included 103 studies, of which 15 used RMBC. Of these, 9 were RCTs that were meta-analyzed. RMBC interventions varied in effectiveness, generally showing small but significant effects on symptom-specific outcomes, with notable effects on mania symptoms and empowerment. The mean adherence rate across studies to all tracking items was 74.5% (SD 13.98; n=38). More prompts per day, but not more items per prompt, were associated with lower adherence. Adverse effects were infrequently reported and included technical problems and psychological distress. Concerns about bias were raised, particularly regarding participants’ awareness of the interventions and potential deviations from the intended protocols.

Although RMBC shows growing potential in improving and tailoring psychiatric care to individual needs, the evidence of its clinical effectiveness is still limited. However, we found potential effects on mania symptoms and empowerment. Overall, there were only a few RCTs with formal psychiatric diagnoses to be included in our analyses, and these had moderate risks of bias. Future studies assessing RMBC’s effectiveness and long-term efficacy with larger populations are needed.

## Linked entities

- **Diseases:** mental illness (MONDO:0002025)

## Full-text entities

- **Genes:** MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}
- **Diseases:** Mental Disorders (MESH:D001523), MMH (OMIM:603663), Symptom (MESH:D012816), substance use disorders (MESH:D019966), fatigue (MESH:D005221), bipolar disorder (MESH:D001714), MBC (MESH:D019292), borderline personality disorder (MESH:D001883), depression (MESH:D003866), psychosis (MESH:D011618), generalized anxiety disorder (MESH:C000726808), anxiety (MESH:D001007), mental (MESH:D008607), psychological distress (MESH:D012128)
- **Chemicals:** RMBC (-), TAU (MESH:C000609666)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12849610/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12849610/full.md

## References

74 references — full list in the complete paper: https://tomesphere.com/paper/PMC12849610/full.md

---
Source: https://tomesphere.com/paper/PMC12849610